Global Brachial Plexus Injury Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Avulsion, Rupture, Neurapraxia, Axonotemesis, Neurotemesis, and Neuroma.

By Diagnosis;

Clinical Examination, Electrodiagnostic Studies, and Imaging Studies.

By Treatment;

Therapy, and Surgery.

By Indication;

Trauma, Inflammation, Contact Sports, Tumors, Radiation Treatment, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn128383412 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Brachial Plexus Injury Market (USD Million), 2021 - 2031

In the year 2024, the Global Brachial Plexus Injury Market was valued at USD 6,644.06 million. The size of this market is expected to increase to USD 15,153.09 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.5%.

The Global Brachial Plexus Injury Market addresses a condition that arises from damage to the complex network of nerves known as the brachial plexus, located near the neck and shoulder. Brachial plexus injuries can result from various causes, including trauma during childbirth, accidents, sports injuries, or medical procedures. These injuries can lead to partial or complete loss of movement and sensation in the affected arm, impacting an individual's mobility, independence, and quality of life. As such, there is a pressing need for effective treatments and interventions to address the challenges posed by brachial plexus injuries, ranging from rehabilitation therapies to surgical procedures aimed at restoring function and mitigating disability.

The market for brachial plexus injury encompasses a spectrum of healthcare services, diagnostic tools, therapeutic interventions, and assistive devices designed to address the diverse needs of individuals with brachial plexus injuries. Diagnostic modalities such as electromyography (EMG), nerve conduction studies (NCS), magnetic resonance imaging (MRI), and computed tomography (CT) scans are utilized to assess the extent and location of nerve damage, guide treatment decisions, and monitor patient progress. Therapeutic interventions may include physical therapy, occupational therapy, nerve grafting, nerve transfers, and muscle reinnervation procedures, depending on the severity and type of injury. Assistive devices such as braces, splints, and adaptive equipment may be prescribed to support and enhance functional abilities in individuals with brachial plexus injuries, promoting independence and participation in daily activities.

The Global Brachial Plexus Injury Market is driven by factors such as increasing incidence of brachial plexus injuries, rising awareness about treatment options, advancements in surgical techniques and rehabilitation protocols, and growing demand for personalized care and improved outcomes among affected individuals. As healthcare providers and researchers continue to explore innovative approaches to brachial plexus injury management, the market is witnessing the emergence of novel therapies such as nerve regeneration strategies, stem cell therapy, and bioengineered scaffolds for nerve repair. Collaborative efforts between healthcare professionals, academic institutions, and industry stakeholders are essential for advancing the field of brachial plexus injury care, facilitating interdisciplinary research, and translating scientific discoveries into clinical practice.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Diagnosis
    3. Market Snapshot, By Treatment
    4. Market Snapshot, By Indication
    5. Market Snapshot, By Region
  4. Global Brachial Plexus Injury Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Trauma Incidence
        2. Surgical Innovation
        3. Rehabilitation Therapy
      2. Restraints
        1. Limited resources
        2. Surgical challenges
        3. Diagnostic complexity
      3. Opportunities
        1. Nerve Regeneration
        2. Stem Cell Therapy
        3. Surgical Innovation
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Brachial Plexus Injury Market, By Type, 2021 - 2031 (USD Million)
      1. Avulsion
      2. Rupture
      3. Neurapraxia
      4. Axonotemesis
      5. Neurotemesis
      6. Neuroma
    2. Global Brachial Plexus Injury Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Clinical Examination
      2. Electrodiagnostic Studies
      3. Imaging Studies
    3. Global Brachial Plexus Injury Market, By Treatment, 2021 - 2031 (USD Million)
      1. Therapy
      2. Surgery
    4. Global Brachial Plexus Injury Market, By Indication, 2021 - 2031 (USD Million)
      1. Trauma
      2. Inflammation
      3. Contact Sports
      4. Tumors
      5. Radiation Treatment
      6. Others
    5. Global Brachial Plexus Injury Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia/New Zealand
        5. South Korea
        6. ASEAN
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer (U.S.)
      2. Abbvie Inc. (U.S.)
      3. Johnson & Johnson (U.S.)
      4. GlaxoSmithKline (U.S.)
      5. Merck Sharp & Dohme Corp (U.S.)
      6. Novartis AG (Germany)
      7. F. Hoffmann-La Roche Ltd (Switzerland)
      8. Eli Lily and Company (U.S.)
      9. AstraZeneca (U.S.)
      10. Amgen (U.S.)
  7. Analyst Views
  8. Future Outlook of the Market